Thorunn Helgason

2.1k total citations
31 papers, 1.1k citations indexed

About

Thorunn Helgason is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Thorunn Helgason has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 18 papers in Cancer Research and 9 papers in Molecular Biology. Recurrent topics in Thorunn Helgason's work include Breast Cancer Treatment Studies (9 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer Treatment and Pharmacology (6 papers). Thorunn Helgason is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer Treatment and Pharmacology (6 papers). Thorunn Helgason collaborates with scholars based in United States, Netherlands and United Kingdom. Thorunn Helgason's co-authors include Razelle Kurzrock, Stacy L. Moulder, David S. Hong, C L Seidel, Jeffrey C. Allen, John W. Moroney, Filip Jankú, Jennifer K. Litton, Jennifer J. Wheler and Constance T. Albarracin and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Thorunn Helgason

28 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thorunn Helgason United States	15	467	427	342	213	166	31	1.1k
Debora Rasio Italy	16	876 1.9×	467 1.1×	352 1.0×	146 0.7×	259 1.6×	25	1.4k
Hio Chung Kang South Korea	26	1.1k 2.4×	654 1.5×	312 0.9×	218 1.0×	292 1.8×	42	1.8k
Timothy P. Heffernan United States	18	837 1.8×	476 1.1×	378 1.1×	137 0.6×	118 0.7×	38	1.3k
Siddhartha Deb Australia	20	660 1.4×	435 1.0×	244 0.7×	229 1.1×	96 0.6×	48	1.3k
Karin Wadt Denmark	18	701 1.5×	528 1.2×	319 0.9×	133 0.6×	132 0.8×	65	1.4k
Zaida García‐Casado Spain	20	782 1.7×	482 1.1×	427 1.2×	229 1.1×	65 0.4×	79	1.3k
Joan Bolt‐de Vries Netherlands	20	508 1.1×	591 1.4×	598 1.7×	405 1.9×	102 0.6×	34	1.4k
Yvonne T.M. Tsang United States	18	533 1.1×	329 0.8×	211 0.6×	141 0.7×	161 1.0×	24	1.2k
Carolina Vicente‐Dueñas Spain	18	728 1.6×	495 1.2×	244 0.7×	124 0.6×	208 1.3×	41	1.2k
Roberto A. Leon‐Ferre United States	15	275 0.6×	447 1.0×	284 0.8×	176 0.8×	93 0.6×	53	989

Countries citing papers authored by Thorunn Helgason

Since Specialization

Citations

This map shows the geographic impact of Thorunn Helgason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thorunn Helgason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thorunn Helgason more than expected).

Fields of papers citing papers by Thorunn Helgason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thorunn Helgason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thorunn Helgason. The network helps show where Thorunn Helgason may publish in the future.

Co-authorship network of co-authors of Thorunn Helgason

This figure shows the co-authorship network connecting the top 25 collaborators of Thorunn Helgason. A scholar is included among the top collaborators of Thorunn Helgason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thorunn Helgason. Thorunn Helgason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Helgason, Thorunn, Senthil Damodaran, Kenneth R. Hess, W. Fraser Symmans, & Stacy L. Moulder. (2019). CLO19-036: Folate Receptor alpha Expression in Metastatic Triple-Negative Breast Cancer (TNBC). Journal of the National Comprehensive Cancer Network. 17(3.5). CLO19–36. 2 indexed citations

Basho, Reva, Clinton Yam, Michael Z. Gilcrease, et al.. (2018). Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. The Oncologist. 23(11). 1300–1309. 45 indexed citations

Damodaran, Senthil, Thorunn Helgason, Elizabeth A. Mittendorf, et al.. (2017). A phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) including a lead-in cohort to establish activity in patients with metastatic TNBC. Annals of Oncology. 28. v106–v106. 1 indexed citations

Yam, Clinton, Kenneth R. Hess, Jennifer K. Litton, et al.. (2017). A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS).. Journal of Clinical Oncology. 35(15_suppl). TPS590–TPS590. 4 indexed citations

Litton, Jennifer K., Marion E. Scoggins, Rashmi K. Murthy, et al.. (2017). A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. npj Breast Cancer. 3(1). 49–49. 48 indexed citations

Basho, Reva, Michael Z. Gilcrease, Rashmi K. Murthy, et al.. (2016). Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology. 3(4). 509–509. 152 indexed citations

Gilcrease, Michael Z., Thorunn Helgason, Funda Meric‐Bernstam, et al.. (2016). Abstract P3-14-02: Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. Cancer Research. 76(4_Supplement). P3–14. 3 indexed citations

Moulder, Stacy L., Thorunn Helgason, Filip Jankú, et al.. (2015). Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Annals of Oncology. 26(7). 1346–1352. 50 indexed citations

Jain, Rajul K., David S. Hong, Aung Naing, et al.. (2015). Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle. 14(21). 3434–3440. 6 indexed citations

10.

González-Angulo, Ana M., Funda Meric‐Bernstam, Sant P. Chawla, et al.. (2013). Weekly nab -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clinical Cancer Research. 19(19). 5474–5484. 63 indexed citations

11.

Wheler, Jennifer J., David S. Hong, Stephen G. Swisher, et al.. (2013). Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses. Oncotarget. 4(6). 890–898. 30 indexed citations

12.

Jankú, Filip, Razelle Kurzrock, Thorunn Helgason, et al.. (2013). Abstract C120: Genomic landscape in advanced metaplastic breast cancer and outcomes with mTOR targeted therapy.. Molecular Cancer Therapeutics. 12(11_Supplement). C120–C120. 2 indexed citations

13.

Moroney, John W., Siqing Fu, Stacy L. Moulder, et al.. (2012). Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity. Clinical Cancer Research. 18(20). 5796–5805. 77 indexed citations

14.

Moulder, Stacy L., John W. Moroney, Thorunn Helgason, et al.. (2011). Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. Journal of Clinical Oncology. 29(19). e572–e575. 54 indexed citations

15.

Moroney, John W., Matthew Schlumbrecht, Thorunn Helgason, et al.. (2011). A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies. Clinical Cancer Research. 17(21). 6840–6846. 42 indexed citations

16.

Vlierberghe, Pieter Van, Martine van Grotel, H. Berna Beverloo, et al.. (2006). The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 108(10). 3520–3529. 123 indexed citations

17.

Abramowitz, Joel, et al.. (2000). Expression of Plasma Membrane Calcium ATPases in Phenotypically Distinct Canine Vascular Smooth Muscle Cells. Journal of Molecular and Cellular Cardiology. 32(5). 777–789. 13 indexed citations

18.

Seidel, C L, Thorunn Helgason, Jeffrey C. Allen, & Charmaine D. Wilson. (1997). Migratory abilities of different vascular cells from the tunica media of canine vessels. American Journal of Physiology-Cell Physiology. 272(3). C847–C852. 27 indexed citations

19.

Holifield, Bruce F., Thorunn Helgason, Addison A. Taylor, et al.. (1996). Differentiated vascular myocytes: are they involved in neointimal formation?. Journal of Clinical Investigation. 97(3). 814–825. 104 indexed citations

20.

Ennos, Richard A., et al.. (1995). Genetic relationships among larch species based on analysis of restriction fragment variation for chBoropBast DNA. Canadian Journal of Forest Research. 25(7). 1197–1202. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact